Do you want to read an article? Please log in or register.
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Type 2 Diabetes
COMMENTED
Related content
Type 2 Diabetes
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Lancet.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators.
doi: 10.1016/S0140-
Diabetes - GeneralType 2 Diabetes
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
Lancet Diabetes Endocrinol.
Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C
doi: 10.1016/
Diabetes - GeneralGlycemic Control
Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials
Diabetes Obes Metab.
Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC
doi: 10.1111/dom.13237.
Type 2 DiabetesDiabetic Complications
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
Diabetes Care.
Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE, CARMELINA investigators.
doi: 10.2337/dc19-0783.
Type 2 DiabetesGlycemic Control
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Lancet Diabetes Endocrinol.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
doi: 10.1016/S2213-8587(17)
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials
Diabetes Technol Ther.
Sun D, Zhang X, Hou XX
doi: 10.1089/dia.2018.0132.
Diabetes - GeneralType 2 Diabetes
Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial
Lancet Diabetes Endocrinol.
Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S, Faghmous J
doi: 10.1016/
COMMENTED
Type 2 Diabetes
Effects of zinc supplementation on lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Nutr Metab Cardiovasc Dis.
Asbaghi O, Sadeghian M, Fouladvand F, Panahande B, Nasiri M, Khodadost M, Shokri A, Pirouzi A, Sadeghi O
doi: 10.1016/j.numecd.2020.03.021.
COMMENTED
Type 2 Diabetes
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Lancet Diabetes Endocrinol.
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E
doi: 10.1016/S2213-8587